These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19446332)

  • 1. Unusual myeloma relapse after thalidomide therapy: the dark side of the moon?
    Balleari E; Bruzzone A
    Leuk Res; 2009 Sep; 33(9):1164-5. PubMed ID: 19446332
    [No Abstract]   [Full Text] [Related]  

  • 2. Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary disease.
    Candoni A; Simeone E; Fanin R
    Am J Hematol; 2008 Aug; 83(8):680-1. PubMed ID: 18459108
    [No Abstract]   [Full Text] [Related]  

  • 3. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
    Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
    Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 5. Thalidomide as anti-inflammatory therapy for multiple myeloma.
    Mehta P; Hussein M
    Leukemia; 2003 Nov; 17(11):2237-8; author reply 2238. PubMed ID: 12931217
    [No Abstract]   [Full Text] [Related]  

  • 6. [Multiple myeloma and neovascularization].
    Hattori Y
    Nihon Naika Gakkai Zasshi; 2002 Sep; 91 Suppl():121-6. PubMed ID: 12577958
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple myeloma: challenges and opportunities.
    Joshua D; Brown R; Ho PJ
    Methods Mol Med; 2005; 113():1-4. PubMed ID: 15968090
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma.
    Hus M; Dmoszyńska A; Kocki J; Hus I; Jawniak D; Adamczyk-Cioch M; Grzasko N
    Leukemia; 2005 Aug; 19(8):1497-9. PubMed ID: 15920492
    [No Abstract]   [Full Text] [Related]  

  • 9. Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment.
    Prescrire Int; 2009 Apr; 18(100):49-52. PubMed ID: 19585712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding myeloma cancer stem cells.
    Pascutti F; Cunha LL; Rizzatti EG; Colleoni GW
    Immunotherapy; 2013 Dec; 5(12):1291-4. PubMed ID: 24283839
    [No Abstract]   [Full Text] [Related]  

  • 12. Myeloma, thalidomide and thrombosis.
    Hönemann D; Prince HM
    Leuk Lymphoma; 2006 Nov; 47(11):2273-5. PubMed ID: 17107896
    [No Abstract]   [Full Text] [Related]  

  • 13. Interstitial granulomatous drug reaction due to thalidomide.
    Yazganoğlu KD; Tambay E; Mete O; Ozkaya E
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):490-3. PubMed ID: 19335735
    [No Abstract]   [Full Text] [Related]  

  • 14. Myeloma-associated polyneuropathy responding to lenalidomide.
    Layzer R; Wolf J
    Neurology; 2009 Sep; 73(10):812-3. PubMed ID: 19738177
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Despite potential side effects, two drugs make a comeback.
    Bjorn G
    Nat Med; 2008 Mar; 14(3):226. PubMed ID: 18323826
    [No Abstract]   [Full Text] [Related]  

  • 17. How drug's rebirth as treatment for cancer fueled price rises.
    Anand G
    Wall St J (East Ed); 2004 Nov; ():A1, A18. PubMed ID: 15586943
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple myeloma and systemic lupus erythematosus in a young woman.
    Okoli K; Irani F; Horvath W
    J Clin Rheumatol; 2009 Sep; 15(6):292-4. PubMed ID: 19734735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
    J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the understanding of the biology and the treatment of multiple myeloma--a cure might be around the corner.
    Mellstedt H
    Acta Oncol; 2000; 39(7):763-4. PubMed ID: 11145429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.